Lineage Cell Therapeutics (LCTX) Current Assets (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Current Assets of $56.2 million for Q1 2026, up 12.36% year-over-year from $50.0 million in Q1 2025, and down 5.06% quarter-over-quarter from $59.2 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Current Assets (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $56.2 million for Q1 2026.
- In Q1 2026, Current Assets rose 12.36% year-over-year to $56.2 million; the TTM figure through Mar 2026 stood at $56.2 million (up 12.36% YoY), while the FY2025 annual figure was $59.2 million, up 16.0% from the prior year.
- Current Assets for Q1 2026 stood at $56.2 million, down from $59.2 million in the prior quarter.
- The five-year high for Current Assets was $81.9 million in Q1 2022, with the low at $34.4 million in Q3 2024.
- The 5-year median for Current Assets is $49.7 million (2023), against an average of $52.2 million.
- The sharpest annual moves came in 2022 and 2024: Current Assets tumbled 46.21% in 2022, then surged 32.66% in 2024.
- Lineage Cell Therapeutics' Current Assets stood at $60.0 million in 2022, then tumbled by 35.93% to $38.4 million in 2023, then soared by 32.66% to $51.0 million in 2024, then increased by 16.0% to $59.2 million in 2025, then decreased by 5.06% to $56.2 million in 2026.
- Business Quant data shows LCTX's Current Assets at $56.2 million in Q1 2026, $59.2 million in Q4 2025, and $42.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 52.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.97 Mn |
| Mar 31, 2026 | 56.16 Mn |
| Dec 31, 2025 | 59.16 Mn |
| Sep 30, 2025 | 42.26 Mn |
| Jun 30, 2025 | 43.84 Mn |
| Mar 31, 2025 | 49.98 Mn |
| Dec 31, 2024 | 51.00 Mn |
| Sep 30, 2024 | 34.40 Mn |
| Jun 30, 2024 | 40.39 Mn |
| Mar 31, 2024 | 45.72 Mn |
| Dec 31, 2023 | 38.44 Mn |
| Sep 30, 2023 | 43.48 Mn |
| Jun 30, 2023 | 48.49 Mn |
| Mar 31, 2023 | 49.66 Mn |
| Dec 31, 2022 | 60.00 Mn |
| Sep 30, 2022 | 68.51 Mn |
| Jun 30, 2022 | 74.03 Mn |
| Mar 31, 2022 | 81.87 Mn |
| Dec 31, 2021 | 111.55 Mn |
| Sep 30, 2021 | 68.34 Mn |